Leerink Raises Genmab (GMAB) Price Target, Keeps Outperform Rating

On Tuesday, June 3, Leerink Partners analysts increased the price target for Genmab A/S (NASDAQ:GMAB) from $29 to $32 and kept an “Outperform” rating.

The decision came after Genmab A/S (NASDAQ:GMAB) shared new data on Rina-S in second-line and endometrial cancer treatments at the American Society of Clinical Oncology (ASCO) Annual Meeting.

Leerink Raises Genmab (GMAB) Price Target, Keeps Outperform Rating

A scientist in a lab using a microscope to develop new treatments for Multiple Myeloma.

The updated data showed positive results and supports the company’s aim to start a Phase 111 trial later this year. Analysts at Leerink Partners see this as a good sign for Genmab A/S’s (NASDAQ:GMAB) future prospects in treating endometrial cancer.

At the ASCO meeting, the company highlighted how Rina-S could address unmet needs in the treatment of endometrial cancer. Genmab A/S (NASDAQ:GMAB) plans to move its clinical trials forward to explore the efficacy of Rina-S.

Genmab A/S (NASDAQ:GMAB) is a Danish biotechnology company that focuses on developing antibody therapeutics for cancer and other serious diseases.

While we acknowledge the potential of GMAB as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GMAB and that has a 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 11 Stocks That Will Bounce Back According To Analysts and 11 Best Stocks Under $15 to Buy According to Hedge Funds.

Disclosure: None.